Esophageal achalasia

Is cold water bad for you? What about drinking from the hose or tap? The facts behind 5 water myths

Retrieved on: 
Tuesday, January 2, 2024
Lead, Myth II: Soulblighter, Water, Grain, Dysphagia, Woman, Mineral, Drinking, Glass, Dysentery, Esophageal achalasia, Health, Headache, Drinking water, Bacteria, Migraine, Life expectancy, Plant, University, Microplastics, River, Temperature, Metal, Public, Cholera, Fresh water, University of Queensland, Exercise, Environment, Bottled water

Myth 1: Cold water is bad for you

Key Points: 
  • Myth 1: Cold water is bad for you
    Some recent TikToks have suggested cold water causes health problems by somehow “contracting blood vessels” and “restricting digestion”.
  • Cold water after exercise in summer or hot water to relax in winter won’t make any difference to your overall health.
  • Hot water is generally a better solvent than cold water, so may dissolve metals and minerals from pipes better.
  • It’s better to fill your cup from the cold tap and get hot water for drinks from the kettle.

Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board

Retrieved on: 
Tuesday, January 10, 2023
Gastroesophageal reflux disease, Constipation, United States Air Force Scientific Advisory Board, Indigestion, The American Journal of Gastroenterology, Gastroparesis, Intestinal pseudo-obstruction, Lacy, Rome, Stomach, Mayo Clinic, IBS, Visceral pain, Gastrointestinal tract, Textbook, Patient, Diet, Research, Irritable bowel syndrome, Clinical and Translational Gastroenterology, Science, Book, Dysphagia, Esophageal achalasia, Esophageal motility disorder, Physician, American Journal, Medical device, Pharmaceutical industry, Gastroenterology

Dr. Lacy has authored over 225 peer reviewed articles

Key Points: 
  • Dr. Lacy has authored over 225 peer reviewed articles
    IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) appointed prominent physician and key opinion leader Brian E. Lacy, M.D., Ph.D., a board-certified gastroenterologist at Mayo Clinic, to its Scientific Advisory Board which is advising the Company on the commercialization of products based on the Biomerica InFoods® Technology platform, beginning with the InFoods® IBS product.
  • I am honored to provide my expertise to Biomerica along with other esteemed members of the Scientific Advisory Board.”
    Dr. Lacy's areas of expertise include irritable bowel syndrome, gastroesophageal reflux disease, dysphagia, achalasia, dyspepsia, gastroparesis, constipation, intestinal pseudo-obstruction and visceral pain.
  • Additionally, Dr. Lacy was the former co-Editor in Chief of the American Journal of Gastroenterology.
  • “Dr.

Esophageal Achalasia Epidemiology Forecast Report 2019-2032 - Focus on US, France, Germany, Italy, Spain, UK, and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022
Health, Other Health, Table, United Kingdom, Disease, SME, Population, Diagnosis, Classification, Esophageal achalasia, Epidemiology, Lists of people executed in the United States, Vaccine, Dentistry, Renewable energy

This "Esophageal Achalasia - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Esophageal Achalasia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Points: 
  • This "Esophageal Achalasia - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Esophageal Achalasia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Esophageal Achalasia epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries.
  • The Esophageal Achalasia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM.
  • The Esophageal Achalasia epidemiology covered in the report provides historical as well as forecasted Esophageal Achalasia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Surgical Table Market to cross USD 1.7 billion by 2028, Says Global Market Insights Inc.

Retrieved on: 
Tuesday, May 10, 2022
Associated Press v. Meltwater U.S. Holdings, Inc., Renewable energy, Table, Population, Esophageal achalasia, Lithotomy, Metal, SCSI Peripheral Device Type, Stryker Corporation, Biotechnology, Composite, Lists of countries and territories, Steris, Prevalence, Patient, Stainless steel, Research report, Risk, Pilonidal disease, Industry, Hospital, Appendicitis, Power, Wilford Hall Ambulatory Surgical Center, Adoption, Surgeon, CAGR, Technology, Research, Getinge Group, USD, Medical device, Dentistry

SELBYVILLE, Del., May 10, 2022 /PRNewswire/ -- The surgical table market value is expected to reach USD 1.7 billion by 2028, according to a new research report by Global Market Insights Inc. Rising number of surgeries due to changing lifestyle, unhealthy food habits is anticipated to impel the market demand.

Key Points: 
  • Furthermore, assistance from the governmental authorities for research and development of novel devices will boost the surgical table market sales.
  • The pediatric surgical table segment was valued at over USD 68 million in 2021 due to the notable adoption of specialty surgical tables for pediatric patients at hospitals and healthcare facilities.
  • Some major findings of the surgical table market report include:
    The ability of technologically advanced surgical tables to perform complex surgical procedures and high adoption rate in hospitals and ambulatory surgical centers will augment the market revenue.
  • China surgical table market is set to cross USD 177 million by 2028.

Achalasia Treatment Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 20, 2022
Health, Pharmaceutical, Row, Matrix, Esophageal achalasia, Porter's five forces analysis, SWOT, Risk management, Retail

The "Achalasia Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Achalasia Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The report on the global achalasia treatment market provides qualitative and quantitative analysis for the period from 2019 to 2027.
  • The report on achalasia treatment market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global achalasia treatment market over the period of 2019 to 2027.
  • Complete coverage of all the segments in the achalasia treatment market to analyze the trends, developments in the global market, and forecast of market size up to 2027.

Coding for Minimally Invasive Endoscopic Treatments Are Now Available

Retrieved on: 
Monday, April 18, 2022
Per-oral endoscopic myotomy, Center, Endoscopy, Esophageal achalasia, Awareness, Government, CPT, Mayo Clinic, Center for Medicare and Medicaid Innovation, EMR, Colonoscopy, Group, FARS, Patient, GI, Endoscopic mucosal resection, ESD, Olympus Corporation, Laparoscopy, Clinical professor, HCPCS, Neoplasm, Safety, Physician, Partnership, HCP, Quality of life, Centers for Medicare & Medicaid Services, American Medical Association, Medicare, Health insurance, Medical device, Medical imaging

CENTER VALLEY, Pa., April 18, 2022 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, today announced its support of a new reimbursement from the Centers for Medicare and Medicaid Services that is expected to improve patient access to Endoscopic Submucosal Dissection (ESD) and for per-oral endoscopic myotomy (POEM). Both are minimally invasive procedures performed endoluminally as an alternative to open or laparoscopic surgery.

Key Points: 
  • Both are minimally invasive procedures performed endoluminally as an alternative to open or laparoscopic surgery.
  • Effective Jan. 1, 2022, a new level 1 CPT code is available for 43497, lower esophageal myotomy transoral, i.e.
  • Compared to Endoscopic Mucosal Resection (EMR), ESD allows for the complete en bloc removal rather than piecemeal resection of large tumors greater than 2 cm.
  • "These decisions also present potential to raise patient and HCP awareness about treatment options that are available.

Olympus Launches HookKnifeJ and TriangleTipKnifeJ

Retrieved on: 
Monday, June 29, 2020
Digestive diseases, Medical specialties, Gastroenterology, Gastrointestinal cancer, RTT, Dysphagia, Esophageal cancer, Esophagus, Esophageal achalasia, Nutcracker esophagus

Olympus, a leader in ESD, is introducing to the U.S. the 510(k) cleared HookKnifeJ for the esophagus, stomach and colon and the TriangleTipKnifeJ for the esophagus and stomach.

Key Points: 
  • Olympus, a leader in ESD, is introducing to the U.S. the 510(k) cleared HookKnifeJ for the esophagus, stomach and colon and the TriangleTipKnifeJ for the esophagus and stomach.
  • The TriangleTipKnifeJ 510(k) clearance comes with a specific indication for Peroral Endoscopic Myotomy (POEM), a type of ESD used to perform esophageal myotomy for patients with swallowing disorders.
  • Customers interested in the TriangleTipKnifeJ or the HookKnifeJ should contact their Olympus sales representative, or Olympus customer service at 1-800-848-9024.
  • Throughout our 100-year history, Olympus has focused on being true to society and making people's lives healthier, safer and more fulfilling.